In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £190.00. The company’s shares opened today at ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal ...

Investors with a lot of money to spend have taken a bullish stance on AstraZeneca AZN. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The issuer is solely responsible for the content of this announcement.

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18,745.88 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is ...

After hours: 7 February at 7:23:25 pm GMT-5 ...